Declining China Dat...
Health Care: Drugs
Vivus (VVUS: NASDAQ)
$14.50 0.98 | 7.25%
05/23/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -139.73M | -47.03M | -75.43M | -54.29M |
| Operating Gains/Losses | -8.00K | 0.00 | 5.95M | -1.08M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -2.84M | 0.00 | 0.00 | -3.11M |
| (Increase) Decrease in Inventories | -22.05M | 118.00K | -3.22M | -148.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 22.20M | 545.00K | -5.69M | -8.72M |
| (Decrease) Increase In Other Current Liabilities | 7.38M | 15.00K | 1.20M | -1.36M |
| (Increase) Decrease In Other Working Capital | 1.15M | 0.00 | 0.00 | -31.86M |
| Other Non-Cash Items | 15.99M | 7.35M | 6.44M | 5.94M |
| Net Cash From Continuing Operations | -131.32M | -39.04M | -67.96M | -96.13M |
| Net Cash From Discontinued Operations | -885.00K | -980.00K | 2.20M | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -132.20M | -40.02M | -65.76M | -96.13M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 174.01M | 132.12M | 274.04M | 177.57M |
| Purchases of Property, Plant & Equipment | -1.67M | -201.00K | -105.00K | -408.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -226.65M | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 700.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -54.31M | -5.49M | 86.42M | -43.44M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 10.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 205.56M | 47.85M | 3.92M | 105.37M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -23.00M | -1.17M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 205.56M | 47.85M | -23.98M | 114.20M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 19.05M | 2.34M | -3.32M | -25.37M |
Portfolios with VVUS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch List
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch
Latest VVUS Headlines from TheStreet
- Bullish Two Hundred Day Moving Average Cross - VVUS 05.23.13 | 04:05 pm
- VIVUS Announces Scientific Presentations 05.22.13 | 07:05 am
- VIVUS Announces Pricing Of Offering Of $220 Million Of 4.50% Convertible Senior Notes 05.16.13 | 07:05 am
- VIVUS Announces Proposed Offering Of Convertible Senior Notes 05.15.13 | 07:05 am
- VIVUS Announces Scientific Presentations 05.14.13 | 07:05 am
- VIVUS Mails Letter To Stockholders Providing Business Update 05.13.13 | 07:05 am
- VIVUS Appoints J. Martin Carroll And Jorge Plutzky, M.D. To Board Of Directors 05.13.13 | 07:05 am
- 4 Stocks Spiking on Big Volume 05.08.13 | 09:05 pm
- VIVUS Reports First Quarter 2013 Financial Results 05.08.13 | 07:05 am
- Happy Day for Arena Bulls, Bears As Belviq Launch Finally Arrives 05.07.13 | 11:05 am
Press Releases for VVUS
- VIVUS Announces FDA Approval Of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies - PR Newswire 04.16.13 | 02:04 pm
- New Obesity Education Program To Premiere At American College Of Physicians (ACP) Annual Meeting - PR Newswire 04.10.13 | 10:04 am
- Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending - PR Newswire 03.25.13 | 06:03 am
- VIVUS Launches Mobile App To Help Patients Lose Weight - PR Newswire 03.07.13 | 07:03 am
- VIVUS Announces New Qsymia Offer - PR Newswire 03.05.13 | 07:03 am
- Study Concludes That Weight Loss With Qsymiaâ¿¢ Significantly Improves Multiple Cardiovascular Disease Risk Factors - PR Newswire 02.01.13 | 07:02 am
- VIVUS Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program - PR Newswire 12.20.12 | 06:12 am
- Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules - PR Newswire 11.12.12 | 07:11 am
- VIVUS Submits REMS Amendment To FDA For Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV - PR Newswire 10.17.12 | 07:10 am
- Express Scripts Joins Qsymia⢠(Phentermine And Topiramate Extended-Release) Certified Home Delivery Pharmacy Network - PR Newswire 10.08.12 | 07:10 am
Partner Headlines for VVUS
- A Look At 3 Obesity Stocks - Seeking Alpha 03.05.13 | 09:03 am
- UPDATE: JP Morgan Cuts PT to $22 on VIVUS Following Q4 Report - Benzinga 02.26.13 | 09:02 am
- Arena's Recent Outperform Call And A Probability Weighted Valuation - Seeking Alpha 02.08.13 | 08:02 am
- Novo Nordisk Earnings Beat Views; Competition Looms - Investor's Business Daily 01.31.13 | 04:01 pm
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- Vivus Reports Earnings And Initial Results Of Qsymia Sales - Seeking Alpha 11.06.12 | 09:11 am
- Vivus Gets Expected European Rejection - Seeking Alpha 10.19.12 | 09:10 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
